Trianni, Inc., a biotechnology company, has launched its Trianni Mouse, a monoclonal antibody discovery platform optimized for isolation of best-in-class therapeutic candidates.
Monoclonal antibodies are the most successful biologic therapeutics on the market. More than 30 have been approved for use in humans and hundreds are currently undergoing testing in clinical trials for a broad range of clinical conditions. Among the options currently available for therapeutic antibody discovery, transgenic mice, such as the Trianni Mouse, are unmatched in their suitability for meeting pharmaceutical research needs.
The Trianni Mouse is an advanced transgenic platform featuring highly engineered antibody genes, generated using state-of-the-art DNA synthesis and genome modification methodology. It replicates the full antibody-producing capacity–or repertoire –of a human being, and features many enhancements designed to improve its performance as a discovery vehicle. Trianni’s technology represents a significantand highly distinctive advance over existing human antibody transgenic mouse platforms.
The Trianni Mouse platform is now available, with additional variations to follow in the first half of 2014. Trianni is actively seeking partnerships with interested biotechnology and pharmaceutical companies.
Trianni took a radically different approach to generating its transgenic mouse platform. This began with the design and chemical synthesis of novel chimeric antibody ‘gene segments’ each composed of human antibody-coding information combined directly with mouse regulatory information. Well over a hundred distinct segments were assembled into large arrays, which were then embedded in the mouse genome in place of their normal mouse counter parts. The outcome was antibody genes that are optimized for function in the mouse yet nonetheless express a full repertoire of human variable domains. The Trianni mouse that carries these unique genes is a validated platform ideal for the isolation of t herapeutic monoclonal antibodies.
Trianni solely focussed on developing and distributing its optimized antibody discovery platform, The Trianni Mouse.